47 results about "Precursor substance" patented technology

The invention relates to the technical field of biology, in particular to an inducer, a reagent combination and application of the inducer in preparation of anisodamine. The inducing agent comprises silver nitrate, acetylsalicylic acid and methyl jasmonate, the components of the inducing agent cooperate with one another, compatibility is high, synergistic interaction can be achieved, and the efficiency of the inducing agent for rapidly converting hyoscyamine into anisodamine is further improved. According to the invention, a suspension cell culture technology is adopted, and an optimized callus culture medium, a precursor substance hyoscyamine and an inducer are combined, so that compared with an initial material anisodamine tanguticum used by an existing anisodamine hydrobromide raw material medicine, the anisodamine hydrobromide raw material medicine has the advantages of short growth cycle, stable content and components, environmental protection and no damage to natural resources; the invention provides a new approach for obtaining a starting material for the production of an anisodamine hydrobromide bulk drug, and is suitable for popularization and application.

The invention relates to a preparation method of a platinum-doped hollow gold nanorod with high photo-thermal stability. The invention belongs to the technical field of nano material preparation. The preparation method comprises the following steps: adding a tellurium precursor substance and a selenium precursor substance into a hydrazine hydrate-containing solution, continuously magnetically stirring, and diluting by using an aqueous solution of lauryl sodium sulfate after the reaction is completed, so as to obtain the tellurium-selenium nanorod; and dispersing the prepared tellurium-selenium nanorod in pure water, adding a gold precursor, a platinum precursor and a modifier at the same time, and then performing centrifugal separation to obtain the platinum-doped hollow gold nanorod. The thermal stability of the hollow gold nanorod is effectively improved through platinum doping, and when the platinum doping proportion is 10% or above, the light and heat stability of the hollow gold nanorod is obviously improved; the positive significance is realized on the full play of the effect of the material in photo-thermal therapy and related combined therapy application.

The invention discloses an ergothioneine-producing recombinant engineering bacterium as well as a construction method and application thereof, and belongs to the technical field of gene recombination fermentation. The method comprises the following steps: by taking escherichia coli as a starting bacterium, carrying out recombinant expression on a histidine trimethyl inner salt cysteine sulfoxide synthetase egt1 gene, an L-histidine methyltransferase egtD gene, a histidine trimethyl inner salt cysteine sulfoxide lyase egt2 gene, a methionine adenosine transferase metK gene, an adenylate kinase adK gene and an adenine phosphoribose transferase apt gene; on this basis, supply of precursor substances including histidine, cysteine and methionine is further improved through metabolic transformation, the yield of the finally obtained recombinant engineering bacterium for producing ergothioneine reaches 2.54 g / L after 48 h of shake-flask culture, the yield of a 5L fermentation tank reaches 18 g / L after further enlarged culture, the yield of ergothioneine is guaranteed while energy consumption and cost are reduced, and the method is suitable for industrial production. The method is suitable for practical popularization.

The invention discloses a method for determining the MeIQx generation level by using ultrahigh pressure liquid chromatography-mass spectrometry. The method comprises the step of detecting the content of MeIQx, the content of precursor substances and the content of intermediate substances generated in an oil-containing system and an oil-free system of a MeIQx chemical simulation system by adopting a high performance liquid chromatograph and a triple quadrupole mass spectrometer connected in series. According to the method, the MeIQx content, precursor substances and intermediate substances in a MeIQx chemical simulation system can be quantitatively detected, the detection speed is high, the precision is high, and through the detection result, the MeIQx inhibition effect and mechanism of the exogenous inhibitor can be scientifically and reasonably analyzed when the exogenous inhibitor is used for frying aquatic products.

The invention discloses a compound with an aryl amide structure and medical application of the compound. The compound is a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof, # imgabs0 #. In-vitro anti-tumor cell experiments are used as carriers to evaluate the efficacy of the compound shown in the formula I in treating various cancers, and it is found that the compound has good in-vitro activity and extremely high selectivity; the compound can be used as a precursor substance for further development of a cancer treatment effect by selectively inhibiting the aldoketoreductase 1C3.

The present application provides a method for preparing a liposome composition. In the method, a containing step is provided, including: providing precursor liposomes wrapping a platinum drug precursor; and culturing the precursor liposomes in a salt solution to convert the platinum drug precursor into a platinum drug to obtain the liposome composition. The precursor liposomes are obtained by the following steps: hydrating the platinum drug to obtain the platinum drug precursor; and adding the platinum drug precursor to a lipid bilayer carrier to obtain the precursor liposomes. The liposome composition prepared by the method has better coating rate and stronger drug loading capacity.

The invention discloses a method for constructing a MeIQx generation simulation system, which comprises the following steps: S1, constructing a system: adding diethylene glycol and water into a reaction tube, adding a certain amount of glycine, creatinine and glucose into the reaction tube, mixing to obtain the MeIQx generation simulation system, and uniformly mixing; s2, construction of different systems: preparing two parts of MeIQx generation simulation systems, adding soybean oil into one part of the MeIQx generation simulation systems to obtain an oil-containing MeIQx generation simulation system, and not adding the other part of the MeIQx generation simulation system to obtain an oil-free MeIQx generation simulation system; s3, adding an inhibitor: respectively adding a certain amount of inhibitor into the two systems, and uniformly mixing; s4, reaction simulation: heating the reaction tubes of the two systems at a certain temperature, and cooling after heating; and S5, substance detection: generating simulation system solutions by the two MeIQx after reaction simulation, and respectively detecting the content of the MeIQx, a precursor substance and an intermediate substance. By constructing a chemical simulation system and adding an exogenous inhibitor, a scientific basis is provided for accurate reduction and control of MeIQx in the high-temperature processing process of aquatic products.

The invention relates to the field of erbium complexes, in particular to a preparation method and application of a metal erbium complex. The chemical formula of the metal erbium complex is (C5H6N) [Er (tfac) 4], and tfac-is deprotonated 1, 1, 1-trifluoroacetylacetone. The metal erbium complex is prepared through solvent volatilization and slow diffusion and a low-temperature crystallization method, namely, an absolute ethyl alcohol solution of erbium chloride, 1, 1, 1-trifluoroacetylacetone and pyridine are added into a three-necked bottle according to the molar ratio of 1: 4: 1, then absolute ethyl alcohol is added, and heating and stirring are conducted; cooling to room temperature, collecting pink and transparent blocky crystals, washing with absolute ethyl alcohol, and drying in vacuum. The metal erbium complex has a remarkable quenching effect on bovine serum albumin in an ethanol solution, and can be used as a drug precursor; the bacteriostasis rate on escherichia coli is 93.36%, and the compound can be used as a bacteriostatic agent.

The present invention discloses a class of compounds having an aromatic amide structure and their applications. The structural formula of the compound is shown below: #imgabs0# The present invention uses in vitro anti-tumor cell experiments as a carrier to evaluate the efficacy of the compound in treating various cancers. It is found that the compound has good in vitro activity and extremely high selectivity, and can be used as a precursor substance for further development to exert cancer treatment effects by selectively inhibiting aldehyde-keto reductase 1C3.

The invention discloses an AKR1C3 selectively activated small molecule drug conjugate and application of the AKR1C3 selectively activated small molecule drug conjugate. The invention discloses a series of compounds with a structure as shown in a general formula I, and also discloses application of the compounds in cancer treatment. The inventor evaluates the efficacy of the compound represented by the general formula I in treatment of various cancers by taking an in-vitro anti-tumor cell experiment as a carrier, and finds that the compound has good in-vitro activity and extremely high selectivity and can be used as a precursor substance for further development of a cancer treatment effect through selective activation of aldoketoreductase 1C3.

The present disclosure relates to the technical field of biotechnology, in particular to carbonyl reductase mutant and its application. Specifically, the present disclosure provides a carbonyl reductase mutant for catalyzing the preparation of (R)-8-chloro-6-hydroxyoctanoic acid ethyl ester from 8-chloro-6-oxooctanoic acid ethyl ester. The mutant protein is a non natural protein and undergoes mutations in three core amino acids related to enzyme catalytic activity in the initial carbonyl reductase. The advantageous effect of the present disclosure is that the carbonyl reductase mutant provided by the present disclosure has the characteristic of efficiently catalyzing the preparation of the precursor substance (R)-8-chloro-6-hydroxyoctanoic acid from 8-chloro-6-oxooctanoic acid ethyl ester, and can efficiently catalyze the oxidation-reduction reaction of 8-chloro-6-oxooctanoic acid, with a product space-time yield of 99.9 g·L−1·h−1 or more.

The utility model relates to a building block type 18F-FDG synthesis module device which comprises a base module, a valve group module and a reagent group module, and the base module is a first building block type module used for installing a reaction tube and providing positioning for the valve group module; the valve group module is a second building block type module which integrates a plurality of control valves, pipelines, QMA columns and solid-phase extraction columns required by 18F-FDG synthesis, and the second building block type module is directly arranged at the mounting position of the first building block type module; the reagent group module is a third building block type module which integrates a plurality of injectors for storing prodrugs and reagents required by the synthesis process and a product purification column, and the third building block type module is directly inserted into the second building block type module. According to the utility model, one 18F-FDG synthesis unit can be formed by simply splicing and combining the three building block type modules, so that the preparation work of 18F-FDG synthesis can be quickly completed, and a plurality of independently running 18F-FDG synthesis units can be placed in one protection box through the combination of a plurality of building block type bases.

An injection device for injecting a drug into a patient is disclosed. The injection device comprises a housing, a first substance chamber configured to receive a first precursor of the drug, and a second substance chamber configured to receive a second precursor of the drug. The injection device also includes a user activatable mechanism configured to open a first fluid path between the first and second substance chambers and permit mixing of the first and second precursor substances to form the drug when activated, and a needle connectable in fluid communication with the drug through a second fluid path. The user activatable mechanism is further configured to open the second fluid path when activated and thereby permit injection of the drug through the needle.

The invention discloses a GlcNAc6P induction component and a method for promoting synthesis of acetylglucosamine. The existing GlcNAc6P sensing element has the problems of serious leakage and small response range, which results in that in the process of regulating and controlling the expression of phosphatase by using the GlcNAc6P sensing element, the phosphatase also has higher expression intensity when intracellular GlcNAc6P is not accumulated, and the supply of precursor substances is influenced. Besides, along with rapid increase of the intracellular GlcNAc6P concentration, the upper limit of the expression quantity of phosphatase is low, the intracellular dephosphorylation requirement cannot be met, and further increase of the GlcNAc yield is limited. Therefore, an existing GlcNAc6P sensing element is optimized, a nagC binding sequence is subjected to directed evolution, expression intensity of repressor protein nagC is optimized, the leakage expression level of the sensor is reduced, and the response range of the sensor is expanded, so that the expression intensity of phosphatase is more effectively and rigorously regulated and controlled to adapt to the change of the concentration of GlcNAc6P in cells in different fermentation periods; and a foundation is laid for producing acetylglucosamine by further transforming recombinant bacteria through metabolic engineering.

The invention relates to the technical field of chemical biological medicines, in particular to a preparation method and application of metal oxide hybrid hollow polydopamine microspheres. PSS is used as a hard template, metal ions and dopamine are adsorbed through static electricity, non-adsorbed metal ions are removed through dialysis, then the metal ions are oxidized into metal oxides through hydrothermal treatment, meanwhile, dopamine is subjected to self-polymerization to form polydopamine, and the composite material with the PSS as a core and the PDA as a shell is formed. A polydopamine-based core-shell structure with uniform size and controllable morphology of metal oxide particles is embedded, a hollow structure is formed along with etching of PSS and metal oxide, and a hollow structure with a nano plug is formed along with secondary coordination nucleation of metal ions after drug loading; due to the existence of the metal oxide, the stability of the adjustable structure of the prodrug is enhanced; the huge cavity structure is beneficial for increasing the drug loading capacity and the packaging efficiency of the anti-tumor small molecule drug; the composite material can realize directional delivery and efficient release of drugs.

The invention belongs to a mass spectrum technology, and particularly provides a sewage poison condition tracing method which comprises the following steps: A1, designing a tracing scheme according to poison condition abnormity of sewage sampling nodes, and the scheme comprises sampling nodes of sewage convergence countercurrent upward hierarchy; a2, collecting and analyzing the concentrations of drug protomers and metabolites thereof of raw water samples of all sampling nodes of the previous layer of the sampling nodes with abnormal toxicity conditions, and identifying the sampling nodes with abnormal toxicity conditions of the layer; circulating to the last-stage sampling node; a3, analyzing the sewage collection condition in the last-stage sampling node, and screening out a minimum building unit of a suspected poison source; and A4, entering the minimum building unit, collecting evidences, and determining the drug-related personnel. The method has the advantages of accurate and rapid tracing and the like.

The application belongs to the technical field of homogeneous catalysis, and discloses application of a ten-core 3d-4f supramolecular nanocage material in catalyzing a three-component Strecker reaction. The ten-core 3d-4f supramolecular nanocage material is used as a nanoreactor to realize synthesis of a biologically active drug precursor through the three-component Strecker reaction. The method has simple operation steps and can realize industrialized preparation. The prepared ten-core 3d-4f supramolecular nanocage material has high catalytic activity, catalytic stability and catalytic efficiency in catalyzing the three-component Strecker reaction.

A tablet (8; p) formed by cohesion of a dose of at least one precursor substance in particulate or powder form, and a method for the production thereof. The tablet has at least one reference surface (S) with one or more graphic identification marks (70, 72), and is characterized in that the at least one reference surface (S) of the precursor substance is substantially free of the at least one graphic identification mark (70, 72) compared to the region of the reference surface (S) of the precursor substance without said graphic identification mark. The one or more graphical identification marks (70, 72) are designed to provide anti-wear protection for the precursor substance at its formation area, such as with a higher degree of cohesiveness.

Disclosed are a method for biological total synthesis of paclitaxel key precursor substance baccatin III, a biological material and use thereof. The bioenzyme composition used in the method comprises a taxane 9α-hydroxylase (T9αH) and a taxane C4-C20 oxetanase (TOT). According to the disclosure, a core component of a baccatin III biosynthetic pathway is identified, a baccatin III artificial synthesis route is constructed, thereby paving the way for efficiently developing a green low-carbon production pathway of taxane products (such as paclitaxel) through synthetic biology.

The invention discloses a temperature control method and system for preparing bilirubin, and the method comprises the steps: obtaining a precursor substance of bilirubin, the precursor substance being biliverdin; dissolving the biliverdin in a physiological buffer solution to form a uniform solution; placing the uniform solution in a temperature control reactor, and carrying out heating pretreatment for a first stage duration so as to ensure that a precursor substance is completely dissolved and a primary reaction is started; the temperature of the temperature control reactor is subjected to dynamic temperature progressive loading of the intermediate reaction for the second stage duration, so that biliverdin is partially converted into bilirubin; and carrying out uniform temperature transition of the third-stage duration on the temperature in the temperature control reactor, cooling the solution to room temperature after the reaction is finished so as to terminate the reaction, carrying out centrifugal separation on the obtained product, and collecting the supernate, thereby obtaining the bilirubin solution. By utilizing the embodiment of the invention, efficient conversion from biliverdin to bilirubin can be realized through accurate multi-stage temperature control, and high-purity bilirubin is obtained.

The application discloses a Saccharomyces cerevisiae de novo synthesis of naringenin engineering strain and a construction method and application thereof, and the engineering strain is constructed by modifying a genome of the Saccharomyces cerevisiae CEN.PK2-1C as follows: substrate competition pathway genes are knocked out, anti-feedback inhibition genes are overexpressed, and the like, so as to improve a metabolic flux j of a precursor substance tyrosine; tyrosine deaminase, 4-coumarate:CoA-ligase, chalcone synthase and chalcone isomerase are expressed heterogeneously, so as to realize de novo synthesis of naringenin. Finally, the yield of naringenin is further improved by high-efficiency expression of Sc4CL and HaCHS at multiple copy sites.

A container (1), which vaporizes a precursor substance and delivers the vaporized precursor substance, comprises: a housing part (12) that forms a boundary of an internal space; and a plurality of sub-carrier trays (4) stacked on each other within the interior space as respective sub-carrier trays (4) forming a gas flow path, at least one of the plurality of sub-carrier trays (4) comprising: a sub-carrier holder (41) for storing the precursor substance; and a support cover (42) abutting the sub-support support (41), substantially comprising at least one pin (44) formed protruding downward toward the sub-support support (41) in such a way as to form a gas flow path (C) covering the entire area of the precursor substance.

This invention relates to the field of pharmaceutical and chemical intermediates technology, and discloses a novel class of substituted phenylethyl-O-β-D-glucuronide compounds. These compounds are generated using substituted phenylethanol as a substrate and 1-fluoro-D-glucuronic acid as a glycosyl donor, catalyzed by β-glucuronyltransferase derived from *E. coli*. The process yield can reach over 95%, and the reaction conditions are mild and environmentally friendly. Substituted phenylethyl-O-β-D-glucuronide can be efficiently used for the determination of β-glucuronidase activity, and its applications are wide-ranging and reliable. The product can meet the needs of pharmaceutical, food, and other fields for β-glucuronidase activity control. It can be used for enzyme activity detection in the auxiliary diagnosis of clinical diseases, and also for enzyme quality control in fruit juice clarification processes in the food industry, drug precursor activation, and glycan structure analysis in the biopharmaceutical field. The product structure has been verified to be accurate by mass spectrometry and 1H NMR spectroscopy, and enzymatic hydrolysis experiments have confirmed its reliable application.

A tablet for extraction of a beverage, formed by cohesion of a dosed amount of a precursor substance in granular or powder form has a reference surface with one or more graphic recognition markings adapted to provide protection from abrasion of the precursor substance, and optionally a higher degree of cohesion, in a region where the one or more graphic recognition markings are formed compared to a region of the reference surface devoid of the graphic recognition markings. A method for producing a tablet for extraction of a beverage, the tablet being formed of a dosed amount of a precursor substance in granular or powder form, involves forming a tablet with self-supporting structure, and making graphic recognition markings on a reference surface of the tablet, adapted to provide protection from abrasion of the precursor substance in a region of the reference surface where the graphic recognition markings are formed.

The invention relates to an anti-alcoholism composition, a liquid preparation with an anti-alcoholism effect and a preparation method and application of the liquid preparation, and belongs to the technical field of physiology. The anti-alcohol composition comprises an NAD (nicotinamide adenine dinucleotide) precursor substance and amino acid, and the NAD precursor substance is one or more of nicotinamide, nicotinamide ribose, nicotinamide mononucleotide or nicotinic acid; and the amino acid is one or more of L-glutamine, L-serine or L-lysine. The special combination of the NAD precursor substance and the amino acid can synergistically accelerate ethanol metabolism, and the alcohol effect dispelling liquid preparation prepared on the basis of the alcohol effect dispelling liquid preparation is flexible in use time, controllable in component and outstanding in alcohol effect dispelling effect, and has very wide application prospects.

The invention discloses an aldehyde ketoreductase 1C3 selective inhibitor with a tricyclic structure and application of the aldehyde ketoreductase 1C3 selective inhibitor. The invention discloses a series of compounds with a structure as shown in a general formula I, and also discloses application of the compounds in cancer treatment. The inventor evaluates the efficacy of the compound represented by the general formula I in treatment of various cancers by taking an in-vitro anti-tumor cell experiment as a carrier, and finds that the compound has good in-vitro activity and can be used as a precursor substance for further development of a cancer treatment effect by inhibiting AKR1C3.

The invention belongs to the field of microorganisms and fermentation engineering, and discloses recombinant escherichia coli for producing valerolactam as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: firstly, modularly optimizing the expression level of a heterologous gene and optimizing a whole-cell catalytic reaction system by using promoter engineering; then, the catabolism of pyruvic acid and the synthesis path of L-lysine are modified, and the supply of precursor substances is enhanced, so that the recombinant escherichia coli realizes de novo synthesis of the valerolactam, and the synthesis efficiency of the valerolactam is remarkably improved. Compared with the prior art, the invention not only provides two methods of whole-cell catalysis and de novo synthesis of the valerolactam, but also effectively avoids the problem of environmental pollution generated in the chemical synthesis process, embodies the concept of green synthesis, and ensures that the yield of the valerolactam reaches a higher level even only at a shake flask level. Important application prospects are provided for efficient synthesis of valerolactam.

A bag (10) for producing a foam-in-bag dunnage material comprises a closed edge portion (16a-c) and, in a non- sealed state of the bag, an open edge portion (16d), the closed and open edge portions (16a-d) delimiting an inner bag volume (22). The invention proposes that a bag structure of the bag (10) comprises a mixing chamber (24) which is adapted to receive foam precursor substances, which is arranged within the inner bag volume (22), which is at least partially and initially delimited against the remainder (28) of the inner bag volume (22), and which in the non-sealed state of the bag (10) is connected to the open edge portion (16d).

The application belongs to the technical field of homogeneous catalysis, and provides application of a ten-core 3d-4f supramolecular nanocage material in catalyzing a three-component aza-Darzens reaction. The application comprises the following steps: mixing an aldehyde compound, an amino benzene compound, ethyl diazoacetate, the ten-core 3d-4f supramolecular nanocage material and an organic solvent, and then performing a reaction to obtain a reaction product, namely completing the three-component aza-Darzens reaction. The ten-core 3d-4f supramolecular nanocage material is used as a catalyst to catalyze the three-component aza-Darzens reaction to realize synthesis of a drug precursor with biological activity, and the catalyst has high catalytic efficiency, the operation steps are simple, and the yield of the target product is also high.